May 27, 2021 7:38am

Trading volumes are likely to lessen heading into the extended Memorial Day holiday weekend, which could exacerbate price moves

My version of the morning’s “indications” is written on what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  

Dow futures are UP +0.02% (+10 points), S&P futures are DOWN -0.15% (-6 points) and NASDAQ futures are DOWN – 0.33% (-45 points)

 

Stock futures were mixed in pre-market trading on Thursday

European stocks were flat,

Asia-Pacific stocks were mixed as investors reacted to the release of Chinese industrial profits which soared 57% year-on-year in April, according to the National Bureau of Statistics.

 

Data Docket: data on U.S. weekly jobless claims; economists expect a total of 425,000 Americans to have filed unemployment benefits in the week ended May 22. In the week prior, jobless claims reached a fresh pandemic-era low of 444,000.

 

Henry’omics:

Investors wait for new labor-market data to gauge the pace of the economic recovery.

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results … thirty (31) to date …  https://www.regmedinvestors.com/articles/11628

 

Wednesday’s evening’s recap: “the past few sessions and the month to date; slippin’, slidin’ and jumping; as I stated this a.m., “the sector will feel the effects of being oversold and recognized by the return of some value!” … https://www.regmedinvestors.com/articles/11929

  • The Nasdaq closed UP + 80.82 points (+0.59%);
  • The IBB closed up +0.60% and XBI closed up +2.17%
  • Sector volume was LOW with 3 of the 27-upside having higher than the 3-month average volume with the volume of 0 of 5-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was down -1.48 points or -7.86% at 17.36
  • Wednesday’s percentage (%) of the 27-upside were +0.67% (CLBS) to +10.86% (BLCM) while the 5-downside ranges from -0.43% (ALNY) to -4.42% (KDNY);

Q2/21

May:  7 positive and 11 negative closes

April: 11 negative and 10 positive closes

Q1/21:

  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Biostage (BSTG): Questions continue … Maintaining Sell and still “pumping” the volume to keep price moving

Biostage (BSTG) closed flat at $1.30 again with 45 shares traded after Tuesday’s flat with 358 shares traded, Monday’s flat with 45 shares traded, Friday’s +$0.02 to $1.32 with 299 shares traded and last Thursday at $1.30 with 1 share traded.

Question#1: After earnings’ release, WHAT is there to invest in, an IND a year old with NO clinical trial, NO management, barely any employees and huge overhead (buildings etc.) expense with WHAT capacity to finance? With only $500 K in the “till” and a two (2) month runway with a $900 K “spend”. Don’t forget the PPP loan remaining as DEBT ($0.4 million).

Question#2: Where is William (BILL) Fodor PhD, the chief scientific officer of BSTG, who was RESPONSIBLE for the IND and the NON - clinical trial initiation, what’s the 1 year plus hold-up? WHY the silence? Did you rush the initial filing to the FDA with-out considering all the ramifications (?); were not 4 adult patients to be tested, implemented and measured before the pediatric IND could be EVEN considered by a secondary filing of results from the first studies?

MINORITY PUBLIC shareholders are waiting, watching and weighing responses to MAINTAIN their RIGHTS.

 

The morning’s indications: I’m starting the Memorial weekend early and “sitting-out” this a.m. re forecasting indications – there is an … escapism in the market and sector.

 

The BOTTOM LINE: I STILL feel like a song from a broken record, “post earnings’ release, BUY some (few) short-term dips but, cautiously”.

My focus has always been “warning analysis” … my advice, trim and skim any new highs if one can!” I also see some lows that could be in the “pick-up” stock game.

My motto, never leave an investor uninformed about what I know!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.